<DOC>
	<DOCNO>NCT01006733</DOCNO>
	<brief_summary>Blood clot contribute death least 100,000 Americans year . Because many death occur suddenly treatment impossible , best treatment prevention . With grant , researcher Missouri , New York , Utah , Illinois , Texas develop strategy improve safety effectiveness clot prevention customize popular blood thinner ( warfarin ) person 's genetic clinical profile . They hypothesize use genetics guide warfarin therapy reduce risk venous thromboembolism ( VTE ) postoperatively . They hypothesize use target international normalized ratio ( INR ) 1.8 non-inferior use target INR 2.5 VTE prevention .</brief_summary>
	<brief_title>Genetics Informatics Trial ( GIFT ) Warfarin Prevent DVT</brief_title>
	<detailed_description>The overall objective Genetics-InFormatics Trial ( GIFT ) Warfarin Prevent DVT elucidate novel strategy improve safety effectiveness warfarin therapy . With study directly respond Health Human Services ( HHS ) priorities advance field personalize medicine prevent venous thromboembolic ( VTE ) disease . In 2007 , Honorable Mike Leavitt , Secretary HHS , announce Personalized Health Care Initiative write key goal , `` … use personal genetic information tailor treatment effectively patient . `` ( 1 ) Recently , President Obama Francis Collins ( Director NIH ) make precision medicine national priority . ( 2 ) Previously , Acting Surgeon General issue Call Action reduce number case VTE United States . ( 3 ) To facilitate precision dose strategy VTE prevention , make publically available non-profit , web application , www.WarfarinDosing.org . A public version www.WarfarinDosing.org estimate warfarin dos initial 5 day warfarin therapy . The version evaluate GIFT provide dose initial 11 day warfarin therapy . Aim 1 : To determine pharmacogenetic-based warfarin therapy affect safety effectiveness warfarin therapy . The intensity anticoagulant therapy measure International Normalized Ratio ( INR ) . During initiation , INR often fall outside therapeutic range . INRs low predispose patient VTE supratherapeutic INR value increase risk bleed . ( 4 , 5 ) Previously , FDA approve label change warfarin/Coumadin™ recommend consider low initial dos patient know certain polymorphisms gene affect warfarin metabolism sensitivity . ( 6 ) However , whether strategy improve safety effectiveness warfarin therapy general unknown . In particular , strategy affect subgroup without genetic variant interest also unknown . Hypothesis 1 : Pharmacogenetic therapy decrease composite risk non-fatal VTE , non-fatal major hemorrhage , death , INR ≥ 4.0 patient , and/or subgroup patient whose pharmacogenetic clinical predict therapeutic maintenance dos differ &gt; 1.0 mg/day . Based meta-analysis prior trial ( 7 ) , anticipate 80 % power simultaneously detect 32 % relative risk reduction composite outcome Aim 1 ( measure chi-square test ) . In clinical arm , base preliminary data , anticipate rate composite outcome 15.7 % clinical arm 10.7 % pharmacogenetic arm . We obtain estimate average rate 13.2 % , rate composite outcome Aim 1 observe initial 775 GIFT participant . The power calculate use two-sided alpha 0.05 test proportion , drop-out rate 2 % , partition ( two-sided ) alpha 0.044 allocated whole population 0.01 high-risk subgroup . Because correlation two subgroup , use alphas preserve overall type 1 error rate 0.05 . Aim 2 : To determine whether warfarin therapy target INR 1.8 non-inferior therapy target INR 2.5 prevent VTE death orthopedic patient . One randomize trial ( PREVENT ) find target INR value 1.5-2.0 prevent 64 % VTE recurrence . ( 8 ) Although trial exclude orthopedic patient , approach endorse American Academy Orthopedic Surgeons ( AAOS ) . On page 15 2007 AAOS guideline ( 9 ) offer follow recommendation VTE prophylaxis around time joint replacement : `` Warfarin , INR goal ≤ 2.0 , start either night night surgery , 2-6 week . '' However , AAOS grade overall evidence VTE prophylaxis population low ( level III ) . The AAOS guideline conflict prior American College Chest Physician ( ACCP ) guideline , ( 10 ) recommend , one ( Grade 1A ) option ( page 338 S ) , use `` …adjusted-dose vitamin K antagonist ( INR target , 2.5 ; range 2.0 3.0 ) . '' Because low target INR value may reduce risk hemorrhage simplify warfarin management ( 8 ) propose test following : Hypothesis 2 : For prevention non-fatal VTE death , target INR 1.8 non-inferior high target INR ( 2.5 ) . Using non-inferiority margin 3 % absolute risk reduction non-fatal VTE death estimate composite rate 5.56 % ( base preliminary GIFT data ) , 83 % power detect non-inferiority target INR 1.8 1600 patient .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>65 year age old must anticipate take warfarin least 4 week VTE prophylaxis hip knee arthroplasty must able give write , informed consent must venous access must institutionalize , incarcerated time enrollment ( nursing home okay ) must life expectancy &gt; 6 month must plan regular INR monitoring willing/able followup 37 week Doppler Ultrasound Baseline INR &gt; 1.35 knowledge CYP2C9 , VKORC1 , CYP4F2 genotype knowledge warfarin dose requirement prior warfarin therapy absolute contraindication allergy warfarin therapy ( e.g . pregnancy ) receive plan receive anticoagulant besides warfarin ( low molecular weight heparin ( LMWH ) subcutaneous heparin deem necessary clinician enrollment , patient allow remain study ) unlikely compliant ( e.g . due history noncompliance , alcoholism ) know thrombophilia , bleed disorder , history serious bleed past 2 year ( unless cause trauma ) personal history venous thromboembolism</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>pharmacogenetics</keyword>
	<keyword>arthroplasty</keyword>
	<keyword>VKORC1</keyword>
	<keyword>thromboembolism</keyword>
	<keyword>warfarin</keyword>
</DOC>